Wedbush Brokers Boost Earnings Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Research analysts at Wedbush upped their Q3 2025 earnings per share estimates for Day One Biopharmaceuticals in a research report issued to clients and investors on Wednesday, April 24th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their previous forecast of ($0.33). Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($1.40) EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Several other research firms have also recently weighed in on DAWN. Piper Sandler restated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. JPMorgan Chase & Co. lifted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $39.33.

Day One Biopharmaceuticals Trading Up 3.6 %

DAWN traded up $0.48 on Friday, hitting $13.69. 281,719 shares of the company’s stock traded hands, compared to its average volume of 803,173. The company’s 50 day simple moving average is $15.23 and its 200-day simple moving average is $13.79. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -5.71 and a beta of -1.48. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $17.85.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Day One Biopharmaceuticals by 8.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock worth $56,807,000 after buying an additional 346,090 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Day One Biopharmaceuticals by 38.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock worth $5,486,000 after acquiring an additional 125,050 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Day One Biopharmaceuticals by 22.4% in the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after acquiring an additional 40,387 shares during the last quarter. TimesSquare Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 41.8% during the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock valued at $14,020,000 after buying an additional 336,910 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Day One Biopharmaceuticals by 5.5% during the third quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock valued at $2,173,000 after buying an additional 9,219 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total transaction of $322,200.00. Following the completion of the sale, the insider now directly owns 1,224,662 shares of the company’s stock, valued at approximately $19,729,304.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Samuel C. Blackman sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the transaction, the insider now owns 1,224,662 shares in the company, valued at approximately $19,729,304.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 2,666 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the transaction, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The disclosure for this sale can be found here. Insiders sold 55,781 shares of company stock valued at $883,160 in the last three months. 8.40% of the stock is owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.